Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6824201 | 0.86 | ALDH1A1 (0.42) | ALDH1A1RAB9ASMN1; SMN2LMNAHCRTR2 | |
| SCHEMBL6325187 | 0.84 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTKMT2ACYP3A4 | |
| SCHEMBL8255637 | 0.83 | ALDH1A1 (0.46) | ALDH1A1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL14174855 | 0.83 | LMNA (0.43) | ALDH1A1RAB9ASMN1; SMN2LMNATHRB | |
| SCHEMBL9546363 | 0.81 | ALDH1A1 (0.47) | ALDH1A1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL11347316 | 0.77 | ALDH1A1 (0.47) | ALDH1A1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL8354033 | 0.77 | KDM4E (0.41) | ALDH1A1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL13887427 | 0.76 | ALDH1A1 (0.41) | ALDH1A1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL4107217 | 0.76 | ALDH1A1 (0.46) | ALDH1A1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL11635095 | 0.76 | RAB9A (0.46) | ALDH1A1RAB9ASMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150140129-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | NOVENTIS, INC. | 2015-05-21 | — | — | US | claimed |
| US-20110262563-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | NOVENTIS, INC. (US) | 2011-10-27 | — | — | US | claimed |
| US-9101537-B2 | Compositions and methods for the prevention and treatment of cardiovascular diseases | REVEN PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150140129-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | NOVENTIS, INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2595636-A2 | METHODS OF TREATING OR AMELIORATING DISEASES AND ENHANCING PERFORMANCE COMPRISING THE USE OF A MAGNETIC DIPOLE STABILIZED SOLUTION | Reven Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012012682-A2 | METHODS OF TREATING OR AMELIORATING DISEASES AND ENHANCING PERFORMANCE COMPRISING THE USE OF A MAGNETIC DIPOLE STABILIZED SOLUTION | HAROON ZISHAN (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20110262563-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | NOVENTIS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150140129-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | TNNI3, TNNC1, TNNT2 | ALDH1A1 1610/4885RAB9A 2731/4885SMN1; SMN2 1565/4885 |
| US-20110262563-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | TNNI3, TNNC1, TNNT2 | ALDH1A1 1610/4885RAB9A 2731/4885SMN1; SMN2 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.